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Brain metastasis frequently occurs in individuals with cancer and is often fatal. The 
interactions between tumor cells and tumor-associated microglia/macrophages (TAMs) in 
different steps of cerebral metastasis formation are poorly characterized. Moreover, the role of 
CX3CR1 in brain metastasis is still unclear. 
 
To elucidate the mechanism underlying brain metastasis formation, our group established a 
syngeneic cerebral metastasis mouse model by combining a chronic cranial window and 
two-photon laser scanning microscopy (TPLSM), which allows the tracking of single 





 mice and red fluorescent Lewis lung 
carcinoma/LL/2/LLc1-Tdt tumor cells were used for in vivo imaging. The role of CX3CR1 
was investigated by comparing the density and cell body volume of TAMs, as well as the fate 
of single metastatic tumor cells in different steps of cerebral metastasis formation. Interactions 
between TAMs and metastatic tumor cells were also assessed by TPLSM. 
 
Herein, we illustrate that TAM density and cell body volume are influenced by metastatic 
tumor cells in different steps of cerebral metastasis formation. Both the density and cell body 
volume of TAMs are increased during tumor growth and decreased in regressing tumors. 
TAMs have close contact with metastatic tumor cells in different steps of cerebral metastasis 
formation, and their interactions in early steps assist in the elimination of tumor cells. 
CX3CR1 deficiency decreases the number of TAMs infiltrated into metastatic tumor lesions, 
but the cell body volume of TAMs is not influenced. The absence of CX3CR1 increases the 
efficiency of cerebral metastasis formation.  
 
Our data indicate that CX3CR1 mediates interactions between TAMs and metastatic tumor 
cells in different steps of cerebral metastasis, and CX3CR1 inhibition facilitates brain 
2 
 
metastasis formation.  
3 
 
2   Introduction 
Brain metastasis commonly occurs in patients with systemic cancer and is associated with a 
dismal prognosis
1
. Therefore, improved therapeutic approaches are urgently needed for 
patients with brain metastasis. The development of novel therapies requires a detailed 
understanding of the complex process of brain metastasis formation and growth within the 
brain microenvironment. 
 
Previous studies have shown that successful metastasis formation requires several steps: 
intravasation of tumor cells into the tumor vasculature, circulation of tumor cells in the 
bloodstream, arrest in capillaries at distant sites, and extravasation into the parenchyma of the 
target organs to start colonization
2
. Accumulating evidence underscores the importance of the 




Parenchymal microglia are the main resident immunological cells in the CNS. Additionally, 
the brain hosts several myeloid cells, including perivascular macrophages, meningeal 
macrophages and choroid plexus macrophages
8
. Although all of these microglia/macrophages 
share numerous myeloid- and macrophage-specific markers (such as IBA1, F4/80, and 
CX3CR1) and exhibit similar immune regulatory functions (such as local immune 
surveillance and removal of debris), early results suggested that they have a distinct 
ontogenesis, with microglia being derived from the yolk sac while macrophages originate 
from hematopoietic stem cells (HSCs) of the bone marrow
8-10
. A former study has shown a 
large number of infiltrating microglia/macrophages in brain metastasis lesions
11-13
; however, 
the exact role of TAMs in brain metastasis is still unclear. Immunohistochemistry results 
indicate that during the initial steps of breast cancer brain metastasis, activation of microglia 
will assist in cancer cell extravasation and progression
14
, while an in vitro assay showed that 







The seven-transmembrane receptor CX3CR1 is a specific receptor for the CX3CL1 
chemokine fractalkine (FKN), which is expressed on monocytes, brain microglia, subsets of 
NK and dendritic cells
15
. CX3CL1 and its receptor CX3CR1 are thought to be important for 
the trafficking of immune cells and intercellular communication between different cell types. 
Research has shown that the CX3CL1/ CX3CR1 system has a crucial tumor-promoting role in 
human glioblastomas via its impact on glioma-infiltrating immune subsets
16
. Thus, CX3CR1 
may act as a potential therapeutic target for cerebral metastasis formation. 
 
To shed light on the interactions between TAMs, and metastasizing tumor cells in the brain 
and to identify the factors (for example: CX3CR1) that mediate their interactions during brain 
metastasis, our group established an animal model that allows the tracking of single 
metastasizing tumor cells from different carcinomas in vivo over time for a period of weeks 







2.1 Cerebral metastasis 
Metastasis means that cancer cells that originate from the primary tumor site spread to a 
distance organ, which is the main cause of death of cancer patients
18
. Among cancer patients, 
10-20% develop brain metastasis. Brain metastasis occurs 10 times more often than primary 
brain tumors
19-21
. Usually, brain metastases occur in the late steps of cancer progression and 
are associated with a poor prognosis. Furthermore, the brain is a sanctuary site for cancer cells, 
as some large molecule drugs are unable to cross the blood-brain barrier (BBB). Brain 





Figure 1: Magnetic resonance images of brain metastases. 
Coronal (left) and transverse (right) section of MRI images from brain metastasis patients. Metastases were 
observed near the ventricle, cerebellum. Edema is also observed because of the metastases. (Image from Carolyn 




Blood flow and tissue volume are the main factors influencing the distribution of brain 
metastasis. Former research has shown that 80% of brain metastases occur in the cerebral 




Clinical symptoms of brain metastases are headache, seizures, and neurological deficit. 
Neuropsychological testing illustrates that 65% of brain metastasis patients suffer from 
cognitive impairment
25,26
, which might be a result of brain tissue damage because of tumor 




Unfortunately, the treatment options are limited for brain metastasis. The commonly used 
therapeutic strategies for brain metastases include surgical removal, chemotherapy, radiation 
therapy, and growth factor inhibitors
27
. For multiple brain metastases, whole-brain radiation 
therapy is recommended. For patients with oligometastases (one to three metastases) or 




2.2 Brain metastasis cascade and organ-specific metastasis 
Brain metastasis is a very complex process. For successful brain metastasis formation, tumor 
cells need to successfully complete several steps known as the metastasis cascade (Figure 2). 
First, single tumor cells have to escape from the primary tumor site, invade the surrounding 
tissue, and then intravasate into the blood stream or the lymphatic system. After circulating in 
the bloodstream, tumor cells must be arrested in the capillary bed of the brain. Afterwards, 
cancer cells need to extravasate successfully to survive in the host tissue. In the early stages of 
metastasis after extravasation, tumor cells will grow through cooption of the pre-existing 
vessels. For continued growth, micrometastases need to develop a new vascular network, a 
process known as angiogenesis. Each of these processes have proven to be very inefficient, 
indicating that in contrast to the large number of circulating tumor cells in the bloodstream, 




With the development of in vivo imaging, more mechanisms behind the veil of metastasis 
have emerged. A murine lung metastasis model revealed that in the early metastatic niche, 
neutrophils, monocytes, dendritic cells, and macrophages have close interactions with 
circulating tumor cells before extravasation
29
. While another study focused on the interaction 
between tumor cells and endothelial cells, their data illustrated that the tumor cells induced 
endothelial cell necroptosis that facilitated extravasation and promoted metastasis. 
Furthermore, targeting the DR6 (death receptor)-mediated necroptosis signaling pathway 
worked as a novel anti-metastatic therapy
30
.   
 
Certain tumor cells shows organ-specific metastasis patterns; for instance, prostate cancer 
cells more easily form bone metastases, while melanoma frequently metastasizes to liver, lung, 
and brain
31,32
. The ‘soil and seed’ hypothesis from Stephen Paget illustrates two factors that 
may influence the organ-specific preference of tumor cells: the characteristics of cancer cells 
and the host organ microenvironment
33
. An alternative hypothesis from pathologist James 
Ewing indicates that circulation patterns of primary and secondary organs lead to 
organ-specific metastasis
34
. A new hypothesis proposes that cancer cells from the primary site 
may introduce some stromal components such as activated fibroblast to the host organs, 






Figure 2: Brain metastasis cascade. 
Brain metastasis is a multistep process. After escape from the primary tumor site, tumor cells must undergo the 
following steps to colonize in the brain parenchyma. a. Arrest in the capillary bed. b. Extravasation, mediated by 
ST6GALNAC5, COX2, and HBEGF genes; activated integrin αvβ3 andβ1 are suggested to involved in arrest and 
adhesion of tumor cells to small capillaries. c-e. Perivascular growth through the cooption of pre-existing vessels 
and angiogenesis, the blood brain barrier (BBB) will be disrupted during tumor proliferation. (Image from April 




2.3 Brain tumor microenvironment 
The main cell types in the brain are neurons, glial cells, including astrocytes, microglia, as 
well as oligodendrocytes, fibroblasts, and pericytes. The blood brain barrier also plays an 
important role in the CNS. Brain tumor progression involves the coevolution of cancer cells 
together with these stromal cells, extracellular matrix, and the vasculature. Under normal 
physiological conditions, the stroma functions as the main barrier against tumorigenesis; 
however, during tumor cell proliferation, this microenvironment may support cancer cell 
progression. 
 
After extravasation into the brain parenchyma, tumor cells will encounter different kinds of 
host stromal cells, such as astrocytes and microglia
27
. Numerous publications have 
demonstrated the accumulation of microglia/macrophages in metastatic brain tumors, and 
their communication determines the fate of metastasis formation
12-14,36,37
. For instance, 
astrocyte-derived exosomes mediate microRNAs interactions with metastatic tumor cells, 
leading to tumor suppressor PTEN loss as well as increased secretion of CCL2, facilitating 
the recruitment of IBA1-positive cells at the micrometastasis site. The recruitment of 
IBA1-positive cells (ionized calcium binding adapter molecule 1, marker for microglia and 
macrophages) enhances tumor proliferation and outgrowth
38
. Not only astrocytes but also 
microglia/macrophages play an important role in cerebral metastasis. The role of TAMs in 
brain metastasis formation will be discussed later in this thesis. Neuron debris may also lead 
to the activation of TAMs
37
. Therefore, targeting stromal cells in the brain tumor mass 







Figure 3: Tumor microenvironment in the CNS tumor mass. 
Brain tumor lesions comprise a very complex microenvironment containing not only tumor cells but also many 
stromal cells, including pericytes, immune cells, and fibroblasts, and newly established vessels developed via a 
process known as angiogenesis. Cancer cells, stromal cells, factors, and vessels constitute the complex 







2.4 CX3CR1 and CX3CL1  
CX3CR1 is a conventional Gαi-coupled seven transmembrane receptor (Figure 4)
40
, which is 





CX3CR1 is defined as the specific receptor of CX3CL1. Unlike any other known chemokine, 
CX3CL1, also known as a novel CX3C chemokine fractalkine (FKN), was found to exist in 
two isoforms: one is membrane-anchored and presented on an extended mucin-like stalk, and 
the other one is a soluble form that results from proteolytic cleavage. CX3CL1 has been 









. The main functions of CX3CR1 are defined as the regulation of immune cell 




Conventionally, CX3CL1 functions as a chemoattractant, and the literature indicates that 
high-affinity interactions between CX3CL1 and CX3CR1 assist the flow of peripheral 
leukocyte capture and adhesion
51









CX3CL1 and CX3CR1 are overexpressed both at mRNA and protein levels in brain tumor 
masses
57-59
. However, the role of the CX3CR1/CX3CL1 axis in brain tumors is still 







, with the upregulation of CX3CR1 leading 
to increased infiltration of immune subsets
58
. Large numbers of infiltrating immune cells in 
tumor lesions may create a microenvironment that suppresses the immune response and 
favors tumor proliferation and metastasis
64
. Targeting nonneoplastic stromal cells can block 
tumor progression and metastasis
62,64-66
. In contrast, other GL261 murine glioma models with 







Accordingly, we deduce that CX3CR1 may mediate the interactions between TAMs and 
metastatic tumor cells, and a deficiency of CX3CR1 may influence the recruitment and 
activation of TAMs and subsequently alter different steps of cerebral metastasis formation. To 
reveal whether CX3CR1 plays a role in the crosstalk of TAMs and metastatic tumor cells, and 
to investigate the role of CX3CR1 in the brain metastasis cascade, we initiated our project to 
focus on this receptor. 
 
Figure 4: Schematic of the CX3C chemokine family. 
CX3CR1 is a seven-transmembrane receptor, and its ligand CX3CL1 has two isoforms: the membrane-anchored 
and soluble form. Soluble CX3CL1 can be formed by proteolytic cleavage of anchored CX3CL1. (adapted 






2.5 CX3CR1GFP/wt and CX3CR1GFP/GFP mice  
The CX3CR1
GFP/wt 
mouse strain was generated in 2000 to investigate the physiological 
interactions between CX3CR1 and its ligand FKN. In heterozygous transgenic mice, the 
physiological 390 bp of one CX3CR1 exon following the CX3CR1 promoter, was replaced 
with EGFP cDNA
15
, resulting in EGFP expression in monocytes, dendritic cells, NK cells, 




 mice are robust, normal in size, fertile, and do not display any 
behavioral abnormalities. After chronic cranial window implantation, TAMs could be 
observed under two-photon microscopy using both normal CX3CR1
GFP/wt
 mice and 
homozygous CX3CR1
GFP/GFP
 mice. Furthermore, in homozygous CX3CR1
GFP/GFP
 mice, both 
alleles were displaced by the GFP gene, resulting in no expression of the CX3CR1 receptor in 




Another reason for using this transgenic mouse strain is that it on the C57/BL6 background, 
which is suitable for murine Lewis lung carcinoma/LL/2/LLc1 cells to establish a syngeneic 




Figure 5: Targeted disruption of the murine CX3CR1 gene. 
14 
 
In heterozygous CX3CR1GFP/wt mice, only one locus is replaced by the GFP gene, and thus, physiological 
CX3CR1 receptor is retained. In homozygous CX3CR1GFP/GFP mice, both alleles are replaced with GFP, 
providing a CX3CR1 deficiency mouse. (Steffen Jung et al., Mol Cell Biol, 200068) 
2.6 Microglia and CNS macrophages 
In 1932, Spanish neuroscientist del Rio-Hortega discovered microglia using silver staining 
and light microscopy
69
. Several decades later, in 2005, through two-photon microscopy, 
scientists found that microglia continually survey their surrounding microenvironment with 




Figure 6: Myeloid cell types in the brain. 
There are different kinds of microglia and macrophages distributed in the brain. In addition to brain microglia, 
other types of macrophages include perivascular, choroid plexus, and meningeal macrophages (image from 
15 
 
Marco Prinz, et al., Nature Review, 201471).  
 
After further investigation, scientists unveiled the mystery of microglia: they are the main 
resident immunological cells in the CNS (central nervous system), constituting 12% of all 
cells in the CNS. Different from macrophages, microglia are long-lived and normally not 
replaced by peripheral cells from the circulation
72
. Moreover, microglia are self-renewable in 
a context-dependent manner to ensure cell expansion. Fate-mapping studies have 
demonstrated that, under homeostatic conditions, microglia originate from HSCs 
(hematopoietic stem cells) of the yolk sac
73-75
, which illustrates that the microglial 
compartment is already established before birth
76
. Microglia are extremely plastic and 
undergo various structural changes. The resting form of microglia consists of a small cell 
body and long branching processes, which are very sensitive to the surrounding changes, 
serving as important sensors of injury and pathology. Once activated by certain stimuli such 
as inflammation, microglia enter an activated state, and their structure changes from a 
branched to an ameboid form or even to a phagocytic morphology. After activation, microglia 





Figure 7: Morphological changes of microglia.  
Certain stimuli can activate resident microglia into the activated amoeboid form, or even phagocytic microglia. 
Resident microglia usually have a small cell body and many processes, which are highly dynamic and keep 
16 
 
scanning the surrounding microenvironment. Once activated by certain stimuli, these processes will be retracted 
and the cell body will enlarge. Activated microglia present the amoeboid form or even the phagocytic form 
(Image from S. Vandenberg, et al., Introduction to the pathobiology of the Nervous system, 201080).  
 
In addition to parenchymal microglia, there are several other myeloid populations in the brain, 
including perivascular, choroid plexus, and meningeal macrophages
81,82
. Macrophages 
originate from the definitive hematopoiesis that starts at E10.5, first in the 
aorta-gonad-mesonephros (AGM) region, or later, at E12.5, in the fetal liver
83,84
. Postnatally, 
monocytes are formed in the bone marrow. Hematopoietic stem cells (HSCs) generate 





Figure 8: Distinct ontogenesis of microglia and macrophages. 
Microglia and CNS macrophages have different origins and development processes. Microglia originate from the 
blood island of the yolk sac and are established before birth, while other CNS macrophages are generated via 
hematopoiesis. Different markers are expressed during different steps of microglial/macrophage development. a 
17 
 
Microglia originate from erythromyeloid progenitors (EMPs) at embryonic day 7.5-8.0 in the yolk sac in mice, 
and subsequently, these cells upregulate different markers as indicated and populate the brain mesenchyme. b 
CNS macrophages are derived from definitive hematopoiesis at E10.5 in the aorta-gonad-mesonephros (AGM), 
or at E12.5 in the fetal liver, or postnatally from bone marrow. Hematopoietic stem cells (HSCs) gradually 
develop into myeloid precursors (MPs) and then into macrophage and/or dendritic cell progenitors (MDPs), and 
surface markers are upregulated during the process of their maturation (Image from Marco Prinz, et al., Nature 
Review, 201471). 
2.7 Role of TAMs in cerebral metastasis formation and brain tumor 
outgrowth  
Former studies have indicated that the majority of stromal cells in brain tumor masses are 
tumor-associated microglia and macrophages (TAMs); for instance, TAMs can make up as 
much as 30-50% of the brain tumor mass
85,86
. Research has repeatedly demonstrated that 
TAMs may play an important role in the processes of brain malignancies. Notably, TAMs 
exhibit both protective and antitumor functions. On the one hand, TAMs are accumulated and 
chronically activated during melanoma brain metastasis formation, the activation of TAMs 
facilitates metastatic tumor outgrowth in mouse brain, and high expression of matrix 
metalloproteinase 3 (MMP3) released from TAMs facilitates tumor cell metastasis
37
. 
Cross-talk between TAMs and metastatic melanoma cells induces matrix metalloproteinase 2 
(MMP2) activation and enhances tumor proliferation and migration
87
. Microglia can facilitate 
metastatic breast cancer outgrowth in a Wnt-dependent manner
36
. A melanoma brain 
metastasis model has shown that the stimulation of TAMs is essential for the outgrowth of 
metastatic tumor cells
37
. Moreover, TAMs may contribute to angiogenesis and anti-angiogenic 
therapy resistance, and assist in tumor cell colonization and proliferation
88-90
. On the other 
hand, LPS-activated TAMs can induce apoptosis of metastatic lung cancer cells
12
. Activation 
of TAMs through Toll-like receptor (TLR9) agonist upregulates phagocytosis-related genes 






Different functions of TAMs may be attributed to their different subtypes. Generally, TAMs 
can be divided into two phenotypes: M1 and M2, which coexist in the tumor 
microenvironment, the proportions and balances of which will determine the fate of the tumor 
mass
92
. For the M1 subtype of TAMs, factors like IL-12, CXCL9, CXCL10, and CD86 are 
upregulated, which activate the immune response and facilitate the eradication of tumor 
cells
93,94
. In contrast, the M2 subtype of TAMs displays tumor-promoting functions based on 
the ability to express growth factors, proangiogenic cytokines, as well as immunosuppressive 
factors to inhibit T cell functions
95-98
. Transformation of the subtypes of TAMs is regarded as 
a good strategy for cancer treatment
94,99
.  
2.8 Two-photon laser scanning microscopy (TPLSM)  
Two-photon excitation is a fluorescence process in which two photons are absorbed by a 




In 1931, Maria Göppert-Mayer established the theoretical basis of two-photon excitation
101
, 
and decades later, this photophysical effect was verified experimentally by Kaiser and Garret 
in 1963. In 1990, the invention of two-photon fluorescence light microscopy by Denk, Webb 
and coworkers
102
 revolutionized three-dimensional (3D) in vivo imaging of cells and tissues. 
 
The principle of one-photon and two photon excitation is similar but slightly different. For 
one-photon excitation, the fluorophore is excited from the electronic ground state to an 
excited state, which requires one photon in the ultraviolet or blue/green spectral range. 
Nevertheless, this process can be achieved by simultaneous absorption of two longer 






Figure 9: One-photon and two-photon microscopy.  
One-photon excitation occurs through the absorption of a single photon, and fluorescence excitation is observed 
throughout the path of the laser beam. Two-photon excitation occurs through the absorption of two lower-energy 
photons, and fluorescence excitation occurs only from a 3D localized spot (Image from Peter TC So, 




Two-photon fluorescence microscopy has both advantages and drawbacks compared with 
confocal microscopy. In contrast to one-photon excitation confocal microscopy, which 
illuminates the specimen with a double inverted cone of light, for two-photon microscopy, 
photobleaching and photodamage are limited to a subfemtoliter volume at the focal point. 
This reduction results in limited damage for the tissue and dramatically increases the viability 
of biological specimens
104
. Thus, TPLSM is more suitable for living organs. 
 
Another advantage of two-photon microscopy is deeper tissue penetration. Two-photon 
excitation microscopy typically uses near-infrared excitation light, which minimizes 
scattering in the tissue. Third, two-photon microscopy minimizes signal loss, as no pinhole 
aperture is required. In confocal microscopy, out-of-focus light is rejected by the usage of a 
pinhole, which leads to a dramatic loss of photons at the confocal pinhole.  
 
Previously, TPLSM was widely used in neuroscience, such as nervous system development, 




The combination of two-photon intravital microscopy and transgenic rodents that express 





Although two-photon microscopy has certain advantages, it also have disadvantages such as a 
lower spatial resolution. The principles of physics reveal that the longer the wavelength of 
excitation light, the lower is the resolution. Two-photon excitation requires the usage of 





Figure 10: A schematic drawing illustrating the light path of a two-photon microscope.  
The laser is excited by Ti-Sapphire and focused on the specimen by a complex light path system. The light signal 
is then obtained by a sensor and transferred to an electronic signal in the PMT. It is then presented on the 





2.9 Aim of this project 
Despite numerous studies attempting to unravel the role of TAMs in brain metastasis, the 
exact function of these tumor-associated TAMs remains elusive and debatable. Thus, 
understanding the interactions between TAMs and metastatic tumor cells can not only reveal 
the mystery of the metastasis brain microenvironment but also help to identify novel 
therapeutic strategies for brain metastasis. 
 
Therefore, the aims of this project are as follows: 
 
to establish a syngeneic cerebral metastasis model for in vivo two-photon microscopy to 
follow the fate of metastatic tumor cells, 
 
to investigate the dynamic interactions of TAMs and metastatic tumor cells during different 
steps of cerebral metastasis formation,  
 











3 Material and Methods 
3.1 Cell culture   
Lewis lung carcinoma/ LL/2 /LLc1-Tdt cells were obtained from the ECACC (European 
Collection of Authenticated Cell Cultures, Catalog No. 90020104). The base medium for this 
cell line is Dulbecco’s Modified Eagle’ Medium (DMEM, Gibco, Catalog No. 41965-039). To 
make complete growth medium, Fetal Bovine Serum (FBS, Biochrom GmbH, Catalog No. S 
0615) was added to DMEM to a final concentration of 10%. After successful transfection with 
pLVX-tdTomato-IRES-Neo plasmid, selection medium should be used, thus G418 (an 
aminoglycoside antibiotic, also known as G418 sulfate and geneticin) (Biochrom GmbH, 
Catalog No. A 2912) should be added to the growth medium to a final concentration of 1000 
µg/ml. A subcultivation radio of 1:4 to 1:6 is recommended, and the cells should be 
subcultured every 2-3 days. Two milliliters of trypsin (Biochrom GmbH, Catalog No. L 2123 
Trypsin/EDTA Solution 0.05%/0.02% (w/v) in PBS) was used to resuspend the cells during 
subculture. The freezing medium contained 10% dimethyl sulfoxide (DMSO, SIGMA, 
Catalog No. D 2650) and 90% FBS. The liquid nitrogen vapor phase was used for long-term 
storage. Cells were regularly tested for mycoplasma infection using the PCR mycoplasma 












3.2 Generation of the pLVX-tdTomato-IRES-Neo vector 
A PCR product with artificial EcoRI and BamHI enzyme restriction sites at the 5‘ and 3‘ ends 
containing the full-length coding sequence of the dimeric red fluorescent protein tdTomato 
was amplified using the plasmid DNA of the ptdTomato vector (Catalog No. 632531, TaKaRa 
Clontech) as a template and subsequently cloned into the EcoRI and BamHI sites of the 
lentiviral expression vector pLVX-IRES-neo (Content of the Lenti X Bicistronic Expression 
System, Catalog No. 632181, TaKaRa Clontech). The resulting construct 




Figure 11: The pLVX-tdTomato-IRES-Neo plasmid.  





3.3 Red fluorescence protein gene transduction of cancer cells  
We used Lipofection (Lipofectamine 3000, Thermo Fisher scientific) to transfect the vector 
pLVX-tdTomato-IRES-Neo (Catalog No. L3000015) into Lewis lung carcinoma/LL2/LLc 
cells according to the manufacturer’s instructions. Briefly, lipo-transfection requires the 
following five steps. First, 5×10
5
 cells must be planted into a 6-well plate and cultured 
overnight. Then, Lipofectamine Reagent is added in Opti-MEM medium (3.75 µl 
Lipofectamine 3000 in 125 µl Opti-MEM). The DNA was diluted in the Opti-MEM medium 
(5 µg/3 µl DNA into 250 µl Opi-MEM). Next, the samples from steps two and three were 
combined and incubated for 5 minutes at room temperature. Finally, the mixed reagents were 
placed in 2 ml growth medium to culture the cells. Two days after transfection, the cells were 
viewed under normal fluorescence microscopy to check whether red fluorescent tumor cells 
could be visualized.  
 
After the cells are successfully transfected with the vector mentioned above, selection 
medium (details described in the cell culture part of this thesis) should be used to successfully 
select transfected cells. This selection medium was also used for long-term cell culture to 
maintain the selection pressure. 
 
3.4 Fluorescence-activated cell sorting (FACS)  
To obtain homogeneous and intense expression of Td-tomato in tumor cell lines, repeated 
FACS sorting (FACS Aria cell sorter, BD Bioscience) was performed.  
 
Flow cytometry and cell sorting was performed as follows. Briefly, cells were resuspended 
and harvested using trypsin. Cells were diluted in FACS buffer (100 ml PBS, Biochrom Cat. 





Before flow cytometry measurement, the cells were filtered using a 30-µm filter 
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Figure 12: Representative FACS-sorting results showing the increase in the fluorescent signal after 
repeated sorting. 
The images show that the mean fluorescence of the tumor cells increased from 464.16 to 4053.62 after repeated 








3.5 Mouse experiments  




 mice and murine Lewis Lung 
carcinoma/LL/2/LLc1-Tdt cells for the experiment. First, a cranial window was prepared. To 
ensure that the inflammatory reaction had completely subsided, we waited for four weeks 
after cranial window preparation, and then tumor cells were injected through the internal 
carotid artery. In the CX3CR1
GFP/wt
 group, a total of 14 mice were successfully injected with 
Lewis lung carcinoma/LL/2/LLc1-Tdt through the intracarotid artery; 8 mice could be used 
for in vivo imaging and further quantitative analysis, and 21 regions could be used for 
statistical analysis. The fate of 107 single cells could be successfully followed up over time. 
In the CX3CR1
GFP/GFP
 group, 12 mice were successfully injected with Lewis lung 
carcinoma/LL/2/LLc1-Tdt through the intracarotid artery; 8 mice could be used for in vivo 
imaging and further quantitative analysis, and 40 regions could be used for statistical analysis. 
The fate of 137 single cells could be successfully followed up over time. 
 
3.5.1 Cranial window preparation 
Cranial windows were prepared as previously described
114,115
. After the mice were deeply 
anesthetized via intraperitoneal (i.p.) injection of MMF (midazolam 5 mg/kg, medetomidine 
0.05 mg/kg, and fentanyl 0.5 mg/kg), a mixture of cefotaxime (250 mg/kg) and 
dexamethasone (2 mg/kg) was subcutaneously injected to reduce infection, inflammation, the 
cortical stress response, and cerebral edema. Then, the animal’s heads were shaved, with 
additional use of depilatory cream. After completion of the preliminary treatment, the mice 
could be fixed on the stereotaxic apparatus. Next, eye ointment was applied to avoid eye 
dehydration and irritation. Povidone-iodine was then used for disinfection, followed by 
removal of the skin and cranial bone. Thereafter, the periosteum was removed and the cortical 
area of interest marked. Later, a thin circular groove around the region of interest was created 
with a dental drill. The thickness of the skull in the groove was checked by gently pushing the 
bone. If the island of the bone could be easily moved without attachment to the skull, we 
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started to remove the cranial bone. After successful skull removal, the dura meter was also 
separated from the leptomeninges and removed. If the superficial capillary was damaged and 
bleeding occurred during the process of dura removal, Tachosil (Takeda Austria, Linz, Austria) 
was applied and the procedure suspended until the bleeding stopped. During the whole 
microsurgical process, both the cranial bone and brain should be kept wet by application of 
0.9% NaCl. The brain was covered with a 6-mm-diameter transparent and sealed with a dental 
cement mixture of ethylcyanoacrylate liquid and methylacrylate powder (Cyano veneer, 
Hager Werken, Duisburg, Germany). The ring was then placed around the cranial window and 
pasted. After surgery, 100 µl Temgesic (0.1 mg/kg/8 hour) should be injected subcutaneously, 
followed by 272 µl Wach (flumazenil 0.1 mg/ml 5 ml, atipamezole 5 mg/ml 0.5 ml, NaCl 3 
ml) 30 mins later to awaken the mouse. The cage was placed on a heating plate until the 
mouse had fully recovered and was freely moving. Six additional dosages of Temgesic were 
injected every 8 hours after the operation. 
 
Figure 13: Cranial window preparation.  
Mice were fixed on a stereotaxic apparatus, and teeth were fixed using a tooth bar, while two ear bars were also 
used for fixation of the head. Mouse eyes were protected using eye ointment. As shown, the cranial window was 
already well-prepared, and the sinus could be visualized through a transparent cranial window. A cranial ring was 
also pasted on the mouse head for future fixation under the objective of TPLSM. 
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3.5.2 Intracarotid artery injection 
The mice were anesthetized via intraperitoneal (i.p.) injection of MMF (midazolam 5 mg/kg, 
medetomidine 0.05 mg/kg, and fentanyl 0.5 mg/kg). After a subcutaneous injection of 
cefotaxime (125 µl 50 mg/ml), the hair was removed from the lower jaw to the manubrium 
using depilatory cream. The mouse was then fixed on the heating mat and the incision area 
disinfected with povidone-iodine. A 1-cm longitudinal cut was created slightly to the midline 
of the neck. Forceps were used to separate the fat and muscle to expose the trachea. The 
salivary gland was then isolated and covered with gauze. Forceps were used to carefully 
separate the fascia overlying the artery. The vagus nerve was pulled gently aside from the 
carotid artery, and forceps were inserted into the intervening space. The vagus nerve was 
pulled aside, and the common carotid artery was isolated. The isolate external carotid artery 
was then isolated using 7-0 silk thread (ETHICON, Cat. No. K 803) with a needle and 
permanently ligate. The common carotid artery was permanently ligated at the anterior side. 
The common carotid artery was temporarily ligated at the posterior side with a slipknot. 
Minor forceps were then used to cut a hole on the common carotid artery, which should be 
close to the anterior ligation position. Thereafter, a self-prepared catheter was inserted into the 
common carotid artery through the hole. A mini vessel clip (AESCULAP, Tuttlingen Germany) 
was used to fix the inserted tube, and then silk thread was used to temporarily ligate the 
inserted part to avoid outflow of the liquid. The ligated threads were temporarily opened, and 
a back blood phenomenon was typically observed. Then, 7.5×10
5 
Lewis lung 
carcinoma/LL/2/LLc1-Tdt (in 150 µl PBS) tumor cells (concentration 5×10
6
/ml) were slowly 
injected into the common carotid artery in 5 mins. After successful tumor injection, the 
common carotid artery was permanently ligated at the posterior side and the catheter removed. 
A certain amount of NACl was applied to the surgical incision to flush the blood and clean the 
tissue. The skin was sutured followed by a subcutaneous injection of 1 dosage of Temgesic. 
After 30 minutes, 272 µl Wach was subcutaneously injected to wake the mouse. The mouse 
was at 1 hour, 3 hours and 6 hours after the operation. Six more dosages of Temgesic were 





Figure 14: Intracarotid artery injection. 
The catheter was successfully injected into the common carotid artery to ensure that the tumor cells 
travelled only go to the brain through the internal carotid artery via blood flow, the external carotid artery 
was permanently ligated (a), the vascular clamp was used for fixation (b), and the common carotid artery 
on the anterior side was permanently ligated to avoid blood flow from the heart. The blood back 
phenomenon could be observed if surgery was successful (d), and then tumor cells could be injected.  
 
3.5.3 In vivo Two-photon Laser Scanning Microscopy (TPLSM) 
We used a multiphoton LaVision Biotech TrimScope I system connected to an upright 
Olympus microscope, equipped with a MaiTai Laser (690-1040 nm) Spectra Physics and a 
20× water immersion objective (numerical aperture 0.95, Olympus). Single images were 
acquired from different depths, depending on different regions, with z-intervals of 2 μm. The 
excitation wavelength was 920 nm, with 1024 ×1024 pixels, detected by PMTs (G6780-20, 
Hamamatsu). Imspectro (LaVision Biotech) was used as acquisition software. For cerebral 
vessel visualization, we injected 0.2 ml 10 mg/ml FITC-dextran (2 M molecular weight, green, 
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Sigma-Aldrich) through the mouse tail vein. The same regions were followed over time 
(every two days), which were identified according to their vessel structure. The mouse body 
temperature was kept constant using a heating pad with a temperature tester. Mice were 
anesthetized with isoflurane and maintained under a constant flow from 0.8% to 2.0% (as low 
as possible according to the physical condition of the mouse). The laser power was also 
limited to the lowest percentage to avoid phototoxicity.  
 
Figure 15: Setup for TPLSM. 
The mouse was anesthetized with isoflurane and fixed under the objective of TPLSM with the help of a cranial 
ring. Body temperature was kept constant using a heating pat under the mouse abdomen. Epi-fluorescence was 
open at this time; thus, the regions of interest could be visualized under the ocular.    
 
3.5.4 Mouse perfusion 
After the mouse was deeply anaesthetized with MMF (midazolam 5 mg/kg, medetomidine 




The right atrial appendage was cut, and blood flowed out. The left apex was punctured with a 
needle followed by injection of NaCl (0.9%) for approximately 20-50 ml until all the blood 
was replaced with NaCl, at which time the flow became clear. Next, the mouse was perfused 
with 4% formalin. In the first few minutes after formalin injection, the mouse exhibited a 
strong reaction, with shaking legs and tail. Spreading of liquid from the nose indicates an 
incorrect puncture point going directly to the atrium, and puncture angle should be changed. 
After perfusion, the organs were harvested. To isolate the brain, the head was separated from 
the body. The skull was cut through middle line and the line between the two eyes to open the 
cranial cavity. The whole brain was exposed and then gently peeled away. Organs were 
collected in 50-ml falcon tubes with 30 ml 4% formalin and stored at 4 °C. 
 
3.5.5 Organ fixation 
After 1-2 hours of storage in 4% formalin, 10%, 20%, and 30% sucrose was used for 
dehydration. The storage time for different concentration gradients was approximately 24 
hours. After fixation in 30% sucrose, the liquid was absorbed on the surface of the brain with 
soft tissue. Afterwards, the brain was frozen in the liquid nitrogen vapor phase and covered 
with plastic film and foil paper, which were precooled at -20 °C (usually placed in the cutting 
machine). The brain was then placed in the freezer at -80 °C. 
 
3.5.6 Frozen brain tissue sections 
The brain was removed from the -80 °C freezer and placed into the cutting machine. After 
approximately 30 mins, the temperature had increased to be equivalent to the cutting machine, 
which was about -20 °C. Some tissue Tek was applied to the cutting plate, and then the plate 
was placed in the chamber of the cutting machine until it was solidified. The brain was fixed 
on the plate with additional tissue Tek. The brain should be vertically standing in the center of 
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the plate. This process should be done as soon as possible to avoid damage of the freezing 
brain because of hot fingers. The plate was subsequently fixed on the cutting machine. Then, 
the section depth was set, typically at 15 µm. Afterwards, the position of the brain was 
manually regulated until it reached the edge of the cutting knife. After finishing these 
preparative processes, cutting was started. The exact cutting position was determined based 
on the mouse brain atlas. After the best cutting position was determined, two slices per slide 
were collected. The slides were kept at room temperature for approximately 20 mins to dry 
and then placed in a slide box at -20 °C for longer storage. 
 
3.5.7 Imaging processing 
After the original data were acquired using two-photon in vivo microscopy, all the images 
were processed in Imaris. To easily distinguish the images, the green channel was replaced 
with blue color and then merged with the red channel; thus, the colors were manually 
manipulated as shown in the last image, in which the vessel in silver white, tumor cells are 
red, and TAMs are sky blue. 
 
Figure 16: Image processing. 
Representative TPLSM shows the image processing. The images in the left column show the merge of green and 
red channel, the middle column shows the green channel replaced with blue color, and the right column 
illustrates the merge of these two channels. The last image indicates how the colors were manipulated to clearly 




3.5.8 Imaging data analysis 
After original images were acquired using Imspector Pro, Bitplane Imaris Software was used 
for further analysis. To obtain high-quality images, the brightness, contrast, or color balance 
was regulated manually for the whole image. The density and volume of the TAMs were 
quantified in a 100 µm × 100 µm × 40 µm three-dimensional region of interest. TAM 
numbers were calculated semiautomatically using the spots function in Imaris, while the cell 
body volume of these immune cells was measured through the surface function. Spots were 
manually added to the cell body, and then cell numbers were calculated. Lines were drawn 
slice-by-slice around the cell body, and then the three-dimensional structure of the cells was 
established and the volume calculated. Same regions of interest were chosen on different days 
according to the vessel structure. The maximum intensity projection (MIP) function was used 
to obtain 2-dimensional images. 
 
Figure 17: Quantification of both the density and cell body volume of TAMs. 
The MIP (left) image indicates the vessels, TAMs and tumor cells. The region of interest was marked in a square 
box. The number of TAMs in this region (three-dimensional x/y/z 100 µm × 100 µm × 40 µm) was calculated 





3.5.9 Data analysis 
Regions of interest (ROI) were randomly selected, and 25% of the data from CX3CR1
GFP/GFP
 
were double checked by a colleague in a blinded manner to avoid bias. In CX3CR1
GFP/wt
 mice, 
n= 17 ROIs for the control, 3 ROIs before single tumor cell arrival, 6 ROIs upon arrival of 
single tumor cells, 8 ROIs for micrometastasis persistence, 6 ROIs for macrometastasis 
persistence, and 8 ROIs after micrometastasis regressed regions, were calculated in 8 mice 
with metastasis and 3 control mice. In CX3CR1
GFP/GFP
 mice, n=18 ROIs for the control, 7 
ROIs before single tumor cell arrival, 15 ROIs upon arrival of single tumor cells, 17 ROIs for 
micrometastasis persistence, 14 ROIs for macrometastasis persistence, and 6 ROIs after 
micrometastasis regressed, were calculated in 8 mice with metastasis and 3 control mice. 
GraphPad software was used to analyze all the data. Statistical differences between multiple 
groups were assessed by the Mann-Whitney-U test. The Chi-square test or Fisher's exact test 
was used for the metastatic cascade depending on the number of samples; if n≥40, the 
Chi-square test was used, and if n<40, Fisher's exact test was used. P<0.05 was regarded as 
statistically significant.  
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4 Results  
4.1 Stable transfection of the Lewis lung carcinoma/LL/2/LLc-Tdt cell line 
To track single metastatic tumor cells in the brain cortex under 2PM, stable fluorescent 
protein was transfected and expressed in the tumor cell line. Td-tomato was selected 
considering its brightness and photostability.  
 
Tdtomato consists of two genetically fused dtomato genes and forms an intramolecular dimer 
in the cytoplasm
116
. This tandem dimer structure plays an important role in the brightness of 
Tdtomato protein, which makes it an outstanding in vivo imaging candidate. Tdtomato is 
widely used in in vivo models, and in a breast cancer metastasis mouse model, tdtomato could 




As Lewis lung carcinoma/LL/2/LLc1-Tdt cells are a semiadherent cell line, lipofection was 
used to transfect the pLVX-tdTomato-IRES-Neo plasmid carrying the tdtomato sequence. 
Compared with other transfection strategies such as electroporation, lipofection is easy to 
perform with high efficiency. One day after lipofection, red fluorescent cells could already be 
observed under microscopy. To select transfected and nontransfected cells, G418 was used. A 
concentration gradient assay of G418 showed that 1000 µg/ml was a demarcation point for 
normal Lewis lung carcinoma/LL/2/LLc1-Tdt cells, representing the highest concentration in 
which they could survive. Thus, it was used as the selection concentration. Moreover, no 
morphological nor proliferation differences were observed compared with normal Lewis lung 
carcinoma/LL/2/LLc1-Tdt cells during in vitro cultivation, indicating that Tdtomato plasmid 
transfection did not change the biological characteristics of Lewis lung 
carcinoma/LL/2/LLc1-Tdt cells. 
 
To obtain stable and highly fluorescent cells, repeated FACs-sorting was performed. During 
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each round of sorting, approximately 10% of the cells with the highest fluorescent signal were 
sorted and subcultured. G418 was also used to maintain the selection pressure. After sorting 
several times, the Lewis lung carcinoma/LL/2/LLc1-Tdt tumor cells were intracranially 
injected into the mouse cortex and imaged under 2PM. 
 
4.2 Establishment of the syngeneic cerebral metastasis model (Lewis lung 
carcinoma/LL/2/LLc1-Tdt cell line) 
After obtaining the highly fluorescent red Lewis lung carcinoma/LL/2/LLc1-Tdt tumor cell 
line, the most important question to be answered was whether these cells would successfully 
form cerebral macrometastases.  
 
Successful macrometastasis formation could be observed after intracarotid injection of Lewis 
lung carcinoma/LL/2/LLc1-TdT. In the CX3CR1
GFP/wt
 group, 14 mice were successfully 
injected with Lewis lung carcinoma cells/LL/2/LLc-Tdt through the intracarotid artery, and 8 
mice could be used for in vivo TPLSM with a survival of 16.13±3.357 days. In contrast, in the 
CX3CR1
GFP/GFP
 group, 12 mice were successfully injected with tumor cells, and 8 mice could 
be used for in vivo TPLSM. The survival time for this group was 14.38±2.825 days. Figure 18 
indicates how macrometastasis formed over a period of 11 days; one day after intracarotid 
artery injection, single metastatic tumor cells could be observed outside the vessel. After 
successful extravasation, tumor cells started to proliferate by cooption of the pre-existing 
vessels. On day 7, the formation of a micrometastasis could be observed. The tumor cells then 
aggressively proliferated, leading to the formation of a macrometastasis on day 11. At that 
time, the vessel structure (dilated vessel diameter, tortuous vessel, nonhierarchical vessel 
architecture) was indicative of angiogenic changes. 
 
These results suggest that the single steps of cerebral metastasis formation could be visualized 
after intracarotid injection of Lewis lung carcinoma/LL/2/LLc1-TdT through the chronic 
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cranial window by using TPLSM, laying a solid foundation for research designed to 
investigate the interactions between metastatic tumor cells and TAMs. 
 
Figure 18: Two-photon microscopy of macrometastasis formation after intracarotid artery injection of 
Lewis lung carcinoma/LL/2/LLc1-Tdt cells. 
Successful Lewis lung carcinoma/LL/2/LLc1-Tdt cerebral macrometastasis formation within 11 days. In 
the first 7 days, Lewis lung carcinoma/LL/2/LLc-Tdt cells (red) were located in the perivascular location. 
From day 9 forward, the cell cluster proliferated by cooption of existing vessels (green after i.v. injection of 
FITC-dextran). Depth: 0-50 µm, the rectangle shows the corresponding region, scale bar, 50 µm.  
 
4.3 Visualization of TAMs and the vasculature in CX3CR1GFP/wt mice  
To visualize microglia/macrophages in the process of cerebral metastasis formation, 
transgenic CX3CR1
GFP 
mice were used. Figure 19 shows an example of TPLSM in 
CX3CR1
GFP/wt 




Figure 19: TPLSM of microglia/macrophages in the CX3CR1
GFP/wt
 mouse brain. As seen from the image, 
microglia/macrophages were evenly distributed in the mouse brain parenchyma, and these resident 
microglia/macrophages exhibited a small cell body and many processes. The morphology of 
microglia/macrophages was heterogeneous, with some exhibiting an ellipsoid and others a longitudinal 
morphology. Depth: 0-200 µm. 
 
To track metastatic tumor cells in different steps of cerebral metastasis formation, especially 
in the early steps: before and after extravasation, the vasculature should also be labeled. 
FITC-dextran was used for in vivo vasculature staining.  
 
After FITC-dextran injection through the tail vein, both TAMs and the vasculature could be 
visualized. As shown in the following image, under normal physiological conditions, 
microglia exhibited a small cell body and many long branching processes (Figure 20). 
Moreover, the vessels could act as a landmark. The same region in mouse brain could be 




morphology, density, and cell body volume of TAMs, could be obtained. 
 
Figure 20: Microglia/macrophages and vessels in CX3CR1
GFP /wt
 mouse brain. 
Microglia/macrophages and vessels were visualized simultaneously in the mouse brain cortex. Resident 
microglia are highlighted in the lower row with a small cell body and long processes. Depth: 38-56 µm, 







4.4 Successful macrometastasis formation of Lewis lung 
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 mice.  
Representative in vivo TPLSM images showing macrometastasis formation after single Lewis lung 





Vessels are highlighted in silver white after i.v. injection of FITC-dextran, while TAMs are shown in bright 
blue (Scale bar, 50 µm). All images are shown as maximum intensity projections with dimensions of 450 
µm × 450 µm × 200 µm (x/y/z). One day after intracarotid artery injection, single tumor cells were 
located in the brain and then rapidly proliferated and formed micrometastases on day 3 and day 5, 
respectively. They then continued to grow to form macrometastases on day 7. 
 
One day after intracarotid artery injection of Lewis lung carcinoma/LL/2/LLc1-Tdt cells, only 







 mice. These single tumor cells then rapidly proliferated and grew to form a 
solid tumor cluster with close cell-cell contacts and associations with the pre-existing 





 mice, respectively. Thereafter, these micrometastases continued to grow, and 
a macrometastasis was formed on day 7. At this time point, single tumor cells were observed 
distant from the main tumor site, reflecting the histopathological growth pattern of advanced 
metastasizing tumor cells in the brain cortex. 
 





mice, the interactions between TAMs and 
metastasizing tumor cells could also be determined, as seen in the images. Single TAMs had 
different colors than tumor cells; thus, both the density and cell body volume of TAMs could 
be analyzed in the region of interest. 
 
4.5 Unsuccessful micrometastasis formation of Lewis lung carcinoma/LL/2 










 mice.  







 mice. All images are shown as maximum intensity projections with 
dimensions of 450 µm × 450 µm (x/y) and a z depth of 1-100 µm and 20-60 µm, respectively. In the 
CX3CR1
GFP/wt
 group, a micrometastasis was formed on day 7 from single metastatic tumor cells on day 3. 
Afterwards, this micrometastasis started to regress, and no tumor cells could be observed on day 11. 
Similarly, in the CX3CR1
GFP/GFP
 group, metastatic tumor cells persisted in brain from day 1 to day 7 and 
regressed on day 9. 
Not all the Lewis lung carcinoma/LL/2/LLc1-Tdt cells we detected could successfully form a 
macrometastasis. We also observed micrometastasis regression before macrometastasis 




mice. Initially, single metastasizing 





, respectively) and then proliferated through the cooption of pre-existing 
vessels to a micrometastasis on day 7. Afterwards, instead of continuing to grow, these 
micrometastases started to regress, and in CX3CR1
GFP/wt
 mice, only one cell could be 
observed after 2 days with complete tumor regression on day 11. In CX3CR1
GFP/GFP
 mice, the 
micrometastasis was already regressed on day 9. 
 
Moreover, as TAMs could be clearly distinguished from metastasizing tumor cells throughout 
the whole process of micrometastasis regression, the interactions between TAMs and 
metastasizing tumor cells during the process of unsuccessful micrometastasis formation could 
also be investigated. By analyzing both the density and cell body volume of TAMs over time 
in the regions of interest in regressing micrometastases, parameter changes could be 
determined.   
 
4.6 Density and cell body volume changes of TAMs in different steps of 
cerebral metastasis formation 
After obtaining images by TPLSM in different steps of cerebral metastasis formation, both the 





 mice and in deficient CX3CR1
GFP/GFP 
mice, with a total of 8 mice per 
group successfully injected with Lewis lung carcinoma/LL/2/LLc1-Tdt cells and used for 
chronic in vivo microscopy and quantification.  
 
Before single tumor cell arrival, both the density and cell body volume of TAMs remained at 
a stable level both in normal CX3CR1
GFP/wt
 mice and in deficient CX3CR1
GFP/GFP 
mice. After 
the arrival of metastasizing tumor cells, these parameters significantly increased in both 
mouse strains. During tumor proliferation, both parameters also rose; however, after tumor 
regression, both the density and cell body volume of the TAMs decreased. Compared with the 
control group mice, there were significantly differences in each step of cerebral metastasis 
formation in both mice strains. 
 
These results indicated that both the density and cell body volume of TAMs were influenced 




Figure 23: Density and cell body volume changes of TAMs in different steps of cerebral metastasis 





A. Density and cell body volume changes of TAMs in different steps of cerebral metastasis formation in 8 
CX3CR1
GFP/wt
 mice and in 3 CX3CR1
GFP/wt
 control mice (region of interest (ROI): n=17 ROIs for the 
control animals, 3 ROIs before single tumor cell arrival, 6 ROIs upon arrival of single tumor cells, 8 
ROIs showing micrometastasis persistence, 6 ROIs showing macrometastasis persistence, 8 ROIs after 
micrometastasis regression (two-tailed Mann-Whitney-U test, *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001; error bars indicate SD). 
B. Comparison of the density and cell body volume of TAMs in different steps of cerebral metastasis 
formation in CX3CR1GFP/GFP mice (n=18 ROIs for the control, 7 ROIs before single tumor cell arrival, 
15 ROIs upon arrival of single tumor cells, 17 ROIs showing micrometastasis persistence, 14 ROIs 
showing macrometastasis persistence, 6 ROIs after micrometastasis regression, calculated in 8 mice 
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with metastasis and 3 control mice). (Two-tailed Mann-Whitney-U test, *P<0.05, **P<0.001, 
***P<0.0001, ****P<0.0001; error bars indicate SD). 
 
4.7 Close contact between TAMs and metastasizing carcinoma/LL/2/LLc1-Tdt 










 mice in the early 
steps of cerebral metastasis. One day after intracarotid artery injection, single metastatic 
Lewis lung carcinoma/LL/2/LLc1-Tdt lung carcinoma cells (Figure 24) were arrested at the 
branch point of small capillary, and the TAMs showed close contact with this arresting branch 
point. Afterwards, on day 3, the tumor cells seemed to be trying to escape from the 
vasculature. Then, on day 5, single tumor cells had already successfully completed 
extravasation. However, instead of continuing to grow after extravasation, these tumor cells 
were phagocytosed by TAMs. On day 9, no tumor cells could be observed. These images 
indicated that the TAMs could exert engulfment functions for metastasizing tumor cells after 
extravasation. Therefore, during the early steps of cerebral metastasis, innate responses 
mediated by TAMs were beneficial and involved the activation of effective surveillance and 












An individual metastatic tumor cell (red) was phagocytosed by TAMs (bright blue) after extravasation 
(magnification shows TAM changes before and after extravasation; depth, 14-30 µm; scale bar, 50 µm). 
 
An interesting phenomena from CX3CR1
GFP/GFP
 mice, as seen in the images (Figure 25 A), 
revealed a red single tumor cell located in an intravascular position over a period of 5 days, 
and the arresting position changed slightly, potentially because of the blood flow. The three 
TAMs that were located the closest to this metastasizing cell were marked. During these 7 
days, no changes in the morphology or density of the TAMs were observed, which indicated 
that the TAMs remained in a relatively stable state while metastasizing tumor cells were 
located in an intravascular position. 
 
Another interesting phenomenon we observed in CX3CR1
GFP/GFP
 mice was the close contact 
between TAMs and metastasizing tumor cells during the early steps of cerebral metastasis 
formation. As shown in the figure (25 B), on day 3 and day 5, single tumor cells were located 
at the branch point of the small capillary in brain cortex. On day 5, the blood brain barrier was 
destroyed, as small parts of the tumor cells appeared to be outside of the vasculature. Seven 
days after intracarotid artery injection, the tumor cells had already disappeared. At this time 
point, the vasculature displayed a pathological condition, as the diameter of the small 
capillary was enlarged. Moreover, the size of the TAMs was also increased, and they 
exhibited close contact with the pathological vessels. From day 9 to day 13, the cell body 





Figure 25: Interactions between TAMs and metastasizing Lewis lung carcinoma/LL/2/LLc1-Tdt lung 





A. TAMs (highlighted by numbers 1/2/3, remained stable over a period of 5 days when the tumor cells 
were arrested in an intravascular location in CX3CR1GFP/GFP mice (depth, 160-210 µm; scale bar, 50 
µm). 
B. Pathological vessel structure and morphological and density changes of TAMs were observed before 
and after single metastasizing Lewis lung carcinoma/LL/2 /LLc1-Tdt tumor cells were arrested at the 
branch point of the small cerebral capillary (depth, 100-150 µm; scale bar, 50 µm). 
 




To compare the density and cell body volume of TAMs in metastatic tumor lesions and 





mice without tumor implantation. 
 
The TPLSM images showed that the resting TAMs were relatively stable, without apparent 
migration or activation both in normal CX3CR1
GFP/wt
 and homozygous CX3CR1
GFP/GFP
 mice.  
 
After acquiring all of these images, both the density and cell body volume of the 
microglia/macrophages were analyzed. As seen from the bar graph, both parameters remained 
at a stable level in both mouse strains. Further, there were no statistically significant 
differences between normal CX3CR1
GFP/wt
 and homozygous CX3CR1
GFP/GFP
 mice, which 















A. Two examples obtained using fluorescence two-photon in vivo images, illustrating the small cell bodies 
and low motility of resting microglia/macrophages both in CX3CR1GFP/wt and CX3CR1GFP/GFP mice. 
(depth, 40-80 µm; scale bar, 50 µm). 
B. Quantification of the density and cell body volume of resting microglia/macrophages in CX3CR1GFP/wt 









 mice  
To further investigate the role of the CX3CR1 receptor in cerebral metastasis formation, both 
the density and cell body volume of TAMs were quantified and the regions of interest 
analyzed in both mice strains. 
 
Representative TPLSM images of the micrometastasis illustrate that more TAMs were present 




 mice. To confirm this finding, 
the TAM density in the micrometastasis tumor mass was quantified in 3D using Imaris. We 
calculated the density of TAMs in metastasizing micrometastasis in all mice that were 





deficient mice. Despite the absence of significant differences between the two 
groups, a trend was apparent, that is, the density of TAMs in the micrometastasis was higher 
in normal CX3CR1
GFP/wt 
compared with homozygous CX3CR1-deficient mice (Figure 27 
CX3CR1
GFP/wt
 (3.72±1.04)×104 /mm3 VS CX3CR1GFP/GFP (2.91±0.70)×104 /mm3; P= 
0.0532 >0.05, no significance, Mann-Whitney U test). 
 
The cell body volume of TAMs correlated with their activation degree
118
. Resting microglia 
usually formed a small cell body, and once activated, the cell body became enlarged. Thus, 
the cell body volume serves as a representative parameter for the activation of microglia. To 
further investigate whether CX3CR1 receptor also affected the activation degree of TAMs, the 
cell body volume of TAMs in regions of interest was quantified. 
 




, no apparent 
differences were observed in the TPLSM images. To further investigate this finding, the cell 
body volume data were quantified and analyzed in more details using Imaris. The data 





 and deficient CX3CR1
GFP/GFP 
mice in the micrometastasis (Figure 27 
CX3CR1
GFP/wt
 411.6±109 μm3/cell VS CX3CR1GFP/GFP 465.0±284.2 μm3/cell; 
P=0.07108>0.05, no significance, Mann-Whitney U test). 
 






A. Fluorescent MPLSM images were used to compare TAMs in the micrometastasis in CX3CR1GFP/wt and 
CX3CR1GFP/GFP mice. Magnification of the images highlights the corresponding regions in blue and red 
channels, and the arrowhead indicates representative TAMs (depth, 0-200 µm in the left column, 0-40 
µm in the middle and right column; scale bar, 50 µm). 
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B. Calculation of the TAMs density and volume in the micrometastasis of CX3CR1GFP/wt and 
CX3CR1GFP/GFP mice. Eight mice were used for the calculation in each group, and 8 and 17 regions 
were quantified in the CX3CR1GFP/wt and CX3CR1GFP/GFP group, respectively.   





 mice  
Both parameters of TAMs were analyzed not only in micrometastases but also in 
macrometastases. Images of the macrometastases were acquired using TPLSM, and then the 
density of TAMs in regions of interest was analyzed using Imaris. The images revealed more 
TAMs in macrometastases in normal CX3CR1
GFP/wt
 than deficient CX3CR1
GFP/GFP
 mice, 
which became even more evident when only one channel was highlighted, as shown in the 
figure (28). Furthermore, the calculated data from 8 mice for the two mouse strains repeatedly 
confirmed the results showing that the density of TAMs in macrometastases was significantly 
higher in normal CX3CR1
GFP/wt
 than in deficient CX3CR1
GFP/GFP 
mice (Figure 28 
CX3CR1
GFP/wt
 (7.719±2.444)×104 /mm3 VS CX3CR1GFP/GFP (4.564±2.515)×104 /mm3; P= 
0.0045<0.05, significance, Mann-Whitney U test). 
 
These results indicate that the CX3CR1 receptor influenced the number of TAMs that 
infiltrated in the micrometastasis and macrometastasis. 
 
Similar to micrometastases, the cell body volume of TAMs recruited to macrometastases was 












662.7±157.2 μm3/cell; P= 0.0698>0.05, no significance, 
Mann-Whitney U test). 
 
These results illustrated that the cell body volume of TAMs recruited into growing metastases, 







 mice.  
 






A. Fluorescence TPLSM images showing TAMs in macrometastases of CX3CR1GFP/wt and 
CX3CR1GFP/GFP mice. Magnification of the images shows TAMs in the corresponding regions, and 
arrowhead indicates single TAMs (depth, 0-200 µm in the left column, 60-100 µm in the right and 
middle column; scale bar, 50 µm). 
B. Quantification of the TAMs density and cell body volume in macrometastases of CX3CR1GFP/wt and 
CX3CR1GFP/GFP mice. The macrometastasis results were from 8 mice per group, and 6 and 14 regions 
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were quantified in the CX3CR1GFP/wt and CX3CR1GFP/GFP group, respectively (two-tailed 
Mann-Whitney-U test, **P<0.01; error bars indicate SD). 
 
4.11 Comparison of the density and cell body volume of TAMs during different 
steps of cerebral metastasis formation 
In addition to the density and cell body volume of TAMs quantified in micrometastases and 
macrometastases, they were also calculated in other steps of cerebral metastasis formation. As 
shown in the figure (29), before single tumor arrival, the density of TAMs was similar in the 
two mouse strains, without a significant difference. However, after the arrival of single tumors, 
significantly more TAMs were observed to infiltrate into the metastatic tumor lesions. 
Additionally, in the micrometastases to macrometastases, a greater number of TAMs were 




 mice.  
 
This finding indicated that the absence of CX3CR1 influenced the number of TAMs that had 
infiltrated into the metastasizing tumor lesion in different steps of cerebral metastasis 
formation. 
 
In contrast to the results obtained for the TAM density in metastasizing tumor lesions, the cell 





 mice. No statistically differences could be detected 





Figure 29: Comparison of the density and cell body volume of TAMs in different steps of cerebral 
metastasis formation.  
The left bar graph indicates the density of TAMs in different steps of cerebral metastasis formation, while 
the right bar graph shows the cell body volume. (In CX3CR1
GFP/wt
 mice: n=17 ROIs for the control, 3 ROIs 
before single tumor cell arrival, 6 ROIs upon arrival of single tumor cells, 8 ROIs for micrometastasis 
persistence, 6 ROIs for macrometastasis persistence, 8 ROIs after micrometastasis regression, calculated in 
8 mice with metastasis and 3 control mice; in CX3CR1
GFP/GFP
 mice: n=18 ROIs for the control, 7 RIOs 
before single tumor cell arrival, 15 ROIs upon arrival of single tumor cells, 17 ROIs for micrometastasis 
persistence, 14 ROIs for macrometastasis persistence, 6 ROIs after micrometastasis regression, calculated 
in 8 mice with metastasis and 3 control mice. Two-tailed Mann-Whitney-U test, *P<0.05, **P<0.01, 
***P<0.01; error bars indicate SD). 
 





 mice  





 mice, respectively. Most of the initially arrested tumor cells were dead or 
displaced before extravasation (57%, 71.5%). Only 42.9% of the initially arrested tumor cells 
in CX3CR1
GFP/wt 




mice showed successfully completed extravasation. This difference was statistically 






often showed successful extravasation. However, only 8.4% (CX3CR1
GFP/wt
) and 13.9% 
(CX3CR1
GFP/GFP
) of the initially arrested tumor cells successfully formed micrometastases. 
Based on this finding in CX3CR1
GFP/wt 
mice, micrometastasis formation was significantly less 
frequent than in CX3CR1
GFP/GFP 
mice (p =0.0044<0.05, Chi-square test). Similarly, 





mice (4.6% vs. 11.6%, respectively). However, this difference was not 















Quantification of the fate of single metastatic tumor cells in CX3CR1GFP/wt and CX3CR1GFP /GFP mice (n=8 mice 
per group) (extravasation versus cell death or displacement, cell death after extravasation versus micrometastasis, 
Chi-square test; macrometastasis versus regression of micrometastasis, Fisher`s exact test,*P<0.05, **P<0.01, 
***P<0.01). 
 
Taken together, our results showed that the metastastic efficiency in our syngeneic model was 
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5.1 Mouse model 
Prior to the development of mouse models, in vitro assays were the main approaches for the 
acquisition of cancer knowledge. Although the usage of in vitro assays provides valuable 
information and remains an important cancer research methodology, their limitations are 
obvious. For instance, such models fail to mimic the interactions between tumor cells and 
stromal cells of the microenvironment in vivo.  
 
Thus, good experimental mouse models are urgently needed for preclinical research to reveal 
the mechanisms and to search for novel therapeutic regimens. Some xenograft mouse models 
have overcome these limitations and achieved certain levels of progress, but the usage of 
immunocompromised mice or subcutaneous implantation could not truly reflect the tumor 
characteristics both at genetic and morphologic levels. Therefore, the establishment of an 
ideal mouse model that could fully resemble human cancer cells has become the first and 




In 2009, a new animal model was established for brain metastasis research using a cranial 
window and two-photon laser scanning microscopy (TPLSM), which allows the tracking of 
single metastasizing tumor cells from different carcinomas in vivo over time for a period of 
weeks, which has been a major challenge in metastasis research over the past decades
17
. 
Compared with other models, the newly established model has several advantages.  
 
First, the newly established model has a high cerebral metastasis formation efficiency. 
Generally, for the establishment of metastasis, mouse model tumor cells are injected in three 
positions: tail vein, intracardiac injection, and intracarotid injection. Tail vein injection of 
cancer cells usually leads to the formation of metastasis in the lung and seldomly the 
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outgrowth of tumor cells in the brain parenchyma. Thus, this technique is usually used for 
lung metastasis instead of brain metastasis models. Intracardiac injection of tumor cells 
frequently leads to the formation of metastases in other organs because only approximately 20% 
of tumor cells can travel to the brain through the blood flow, and tumor growth in the brain 




In our model, cancer cells were injected through the internal carotid artery. To avoid the 
spread of tumor cells to other regions, such as the face, eye, and ear, the external carotid 
artery was ligated. According to our experience, approximately 60% of the mice survived the 
procedure and had tumor cells under the chronic cranial window that could be followed using 
TPLSM. This result is similar to the data published by Yvonne Kienast et al
122
. Other groups 
have injected tumor cells through common carotid artery without ligation of the external 
carotid artery
37,38
, although their data showed that this procedure also led to the formation of 
brain metastasis, and they did not describe the proportion of mice that formed metastasis in 
other parts of the head but not the brain. 
Upon contacting the first author of the Nature paper
38
, she replied that they attempted to ligate 
the external carotid artery, but due to technical difficulty, a high percentage of the 
consequently mice died. They also believed that ligation of external carotid artery should be 
better for establishment of the cerebral metastasis model.  
 
Moreover, in some models, despite using intravital microscopic imaging to investigate the 
interactions between TAMs and metastasizing tumor cells, confocal but not multiphoton laser 
scanning microscopy were used, resulting in a depth of only less than 100 µm, which was not 
enough to investigate the interactions in the deeper cortex of the brain parenchyma
123
. In our 
model, we were able to obtain high-quality images as deep as 300 µm, which allowed us to 




Furthermore, in some cerebral metastasis mouse models, human tumor cell lines and nude 
mice were used
122
. However, this combination is not suitable to answer questions such as the 
role of TAMs in processes of cerebral metastasis formation, as nude mouse carry the foxn 1 
gene mutation, which causes a deteriorated or absent thymus, resulting in an inhibited 
immune system due to a greatly reduced number of T cells
124
. As T cells play an important 
role in antitumor outgrowth, T cell deficiency could not fully simulate patients in the clinic. 
 





 mice on the C57BL6 mouse strain background. Lewis 
lung carcinoma/LL/2/LLc1-Tdt is a cell line established from the lung of a C57BL mouse 
bearing a tumor resulting from implantation of primary Lewis lung carcinoma/LL/2/LLc1-Tdt, 
and matching of the murine tumor cell line and CX3CR1
GFP
 mouse strain to the utmost extent 
simulated cerebral metastasis in the clinic. 
 
Another advantage of our models was that we could analyze the interactions between TAMs 
and tumor cells in 3D. Thus, both the density and volume of TAMs could be followed. 
Compared with other technologies, for example, immunohistochemistry, usually only 2D 
information can be obtained
12,14,125
. Moreover, for immunohistochemistry, large amounts of 
cutting and staining work are required, necessitating large amounts of time and cost to 
determine the exact distribution of metastases in the whole brain. However, in our model, 








5.2 Interactions between TAMs and metastasizing tumor cells in the early 
steps of cerebral metastasis formation 
Numerous researchers have focused on the roles of TAMs in brain tumors. In malignant 
gliomas, TAMs constitute as many as 30-50%
126,127
, while in human brain metastases, they 
can account for as much as 4 to 70%
128
. A large number of TAMs infiltrated in brain tumor 
masses are associated with a poor prognosis
129
. Scientists are attempting to reveal the role of 
TAMs in cerebral metastasis formation and expect to develop novel therapeutic strategies 
through a better understanding of the microenvironment of brain metastases. Former studies 
have shown the dual roles of TAMs in brain tumor progression. On the one hand, they act as 
tumor terminators and inhibit brain metastasis via phagocytosis and the release of cytotoxic 
factors
108,109
; on the other hand, ongoing inflammation can polarize TAMs into 
immunosuppressive stromal cells that promote tumor growth, colonization, angiogenesis, and 




The first question we need to answer concerns how TPLSM reveals the interactions between 
TAMs and tumor cells, using the 3D scan time lapse or only the 3D scan. Although the 3D 
scan time lapse is a good strategy for the timely recording of interactions between cells, the 
extravasation process may require hours or even longer. Thus, 3D scan time lapse is not as 
suitable to follow single metastasizing tumor cells in different steps of cerebral metastasis 
formation. Furthermore, long-term imaging of the same position may lead to phototoxicity 
and pathological changes. Additionally, long-term imaging is challenging for the mice. 
 
Therefore, we chose the 3D scan instead of 3D scan time lapse for our experiments. At first, 
the time interval was 2-3 days; however, we found this time interval to be too long to gain 
sufficient information, as many interesting phenomena occur during the two imaging time 
points. However, conversely, we could not perform in vivo imaging on a daily basis, as 
high-frequency imaging will have severe side effects on the mice. Taking all of this 
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information into consideration, we acquired images every two days to follow regions of 
interest over time. 
 
After the imaging methodology and time interval were determined, we started the 
experiments accordingly and obtained some interesting findings. 
 
In the early steps of cerebral metastasis before extravasation, we found that tumor cells were 
elongated inside the vascular lumen, which is similar to a previous report
14
. However, we also 
found some differences from previous studies, which did not detect significant destruction of 
the vessel wall by immunohistochemistry
14
. In contrast, our data showed an increase in 
vascular diameter during the early steps of cerebral metastasis, and the pathological vascular 
morphology was recovered after regression of the metastatic tumor cells. 
 
Moreover, we also acquired many interesting phenomena that have never been previously 
shown. For instance, previous literature has shown a heterogeneous recruitment and activation 
of TAMs in early steps of cerebral metastasis, either an absence of TAMs when metastatic 
tumor cells arrived in the brain parenchyma
14
 or hyperactivation of TAMs
12
. The diverse 
responses of TAMs seem depends on differ mouse strains and tumor cell lines. Our data 
illustrated that when metastatic tumor cells attempted to escape from the BBB, resident 
immune cells in the brain started the activation process and the first wave of immune 
surveillance. In my opinion, there are two approaches via which TAMs can receive the signal 
from metastasizing tumor cells and become activated. As resident microglia have many motile 
processes extending from the small soma, timely scanning occurs to patrol the brain 
parenchyma
70
. Thus, microglia can be stimulated by direct interactions with metastasizing 
tumor cells. In such cases, the blood brain barrier will be damaged or at least a portion of the 




Another possibility is that TAMs may be activated by certain factors, or cytokines. If tumor 
cells are attempting to escape the vessel to enter the brain cortex, the blood brain barrier will 
be destroyed, damage-associated molecular pattern molecules (DAMPs) will be released from 
the vessel wall
131
, and the surrounding TAMs may receive these signals in a timely manner 
and be stimulated.  
 
Although previous researchers have investigated the interactions between TAMs and 
metastatic tumor cells, most of them have failed to investigate their crosstalk in the early steps 
of cerebral metastasis
12,14,37
. Our data showed that TAMs had close contact with metastatic 
tumor cells in the early steps of cerebral metastasis. This close contact was beneficial for the 
elimination of metastasizing tumor cells, as we observed that TAMs exerted engulfment 
functions for single metastasizing tumor cells after extravasation. These results indicated that 
in the early stages of cerebral metastasis, innate responses mediated by microglia were 
beneficial and involved the activation of effective surveillance and tumoricidal effects, 
resulting in the elimination of single metastasizing cells.  
 
 
5.3 Density and cell body volume of TAMs in different steps of cerebral 
metastasis formation 
The changes in the number and activation degree of TAMs usually indicate different kinds of 
brain damage or injury
70
. For instance, in an Alzheimer’s disease mouse model, increasing 
numbers of microglia promote the elimination of neurons
52
, whereas depletion of microglia 
reduces motor-learning-dependent synapse formation. Also for other diseases: stroke, 









. Some cerebral metastasis research has shown that TAMs 
gradually accumulate and show an enhanced degree of activation during tumor growth
123
; 
however, these data failed to follow the same region over time to compare the density and cell 
body volume changes from single metastasizing tumor cells to micro/macrometastases. 
Further, they could not indicate whether these parameter alterations occurred in regressing 
tumor lesions. 
 
In our metastasis model, TAMs were followed in the same regions from the single tumor cell 
to micro/macrometastases. Our data showed that the densities and cell body volumes of TAMs 
gradually increased when single tumor cells arrived in the brain parenchyma, and the cell 





Significant differences were observed in different steps of cerebral metastasis formation 
compared with control group mice in terms of the TAM density and cell body volume. In 
contrast, in regressing micrometastasis, both parameters were significantly decreased. 
 
These data indicated that both the density and cell body volume of TAMs were influenced by 
metastasizing tumor cells, in different steps of cerebral metastasis the activation degrees of 
TAMs were different, and the larger the tumor size, the greater was the number of infiltrating 
TAMs, and vice versa. 
 
5.4 Factors mediating the interactions between TAMs and metastasizing 
tumor cells 
 
Cross-talk between metastatic tumor cells, TAMs, and other stromal cells facilitates 
establishment of the tumor microenvironment, and it also influences the tumor outcome
92
. 





. These factors include cytokines/chemokines like monocyte 
chemoattractant protein-1 (MCP-1), granulocyte/macrophage-colony stimulating factor 
(GM-CSF), CX3CL1, and CCL
138
; growth factors such as glia cell-derived neurotrophic 
factor (GDNF) and hepatocyte growth factor/scatter factor (HFG/SF)
139
; matrix 
metalloproteinases; and extracellular vesicles such as metabolites (e.g., adenosine 
triphosphate/ATP)
140,141
, proteins, and nucleic acids (e.g., microRNAs: miR-223, miR-124, 




CX3CR1, a G-protein-coupled receptor, and its ligand CX3CL1 (FKN) were first investigated 
in the transendothelial migration of leukocytes during the process of inflammation
148,149
. Their 
interactions may assist in the arrest of leukocytes in the small capillary under flow conditions.  
 
Afterwards, many researchers revealed that CX3CR1 might play an important role in the 
process of tumor progression. For instance, CX3CR1 is overexpressed both at mRNA and 
protein levels in TAMs of malignant human astrocytomas and glioblastomas, regulating the 




In the NF 1 (neurofibromatosis type 1)-associated optic glioma mouse model, CX3CR1 
deficiency reduces TAM numbers and, thus, delays optic glioma formation
61
. Similarly, in the 
hepatic metastasis model, the microenvironment lacking CX3CR1 significantly suppresses 
tumor metastasis
62
. However, other publication have shown that in CX3CR1-deficient mice, 
neither the proliferation of GL261 glioma cells nor the infiltration of microglia and 




The role of CX3CR1 has also been investigated in other type of cancers, such as human colon 
cancer, in which CX3CR1 upregulation is associated with a higher histologic malignancy 
grade and a poor prognosis. Deficiency of CX3CR1 inhibits the accumulation of TAMs in the 
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tumor mass, as well as increases TAM apoptosis. Moreover, angiogenesis is also blocked. 




Some of our data are similar to previous studies, but others are not. For example, we also 
found an absence of CX3CR1 leading to decreased infiltration of TAMs in metastatic tumor 
lesions. However, in contrast to previous studies, we found that CX3CR1 deficiency assisted 
cerebral metastasis formation. This result indicates that the role of CX3CR1 in metastasis may 
differ in different organs.  
 
Although the absence of CX3CR1 reduced TAM infiltration in metastatic tumor lesions, we 
still observed an increased number of TAMs in metastatic tumor lesions compared with 
regions without metastatic tumor growth, illustrating that CX3CR1 was not the only receptor 
mediating the recruitment of TAMs, as many receptors and signaling pathways are involved in 
communications between TAMs and tumor cells, such as CSF-1R
65,99
. Thus, CX3CR1 only 
partially affected their interactions. 
  
5.5 Fate of metastatic tumor cells in the brain 
 
Our data illustrate that the efficiency of cerebral metastasis formation is very low, with only 
approximately 5% and 12% of tumor cells successfully proliferating to generate a large 




 group, respectively. Previous 
studies have also illustrated a low efficiency of metastasis. For instance, B16 melanoma lung 
metastasis experiments showed that 24 hours post-intravenous injection, only 1.5% of tumor 
cells survived, and less than 0.01% of circulating tumor cells in the blood streams formed 
lung metastases in the end
151
. Not only in lung metastasis, but brain metastasis formation 
efficiency is also very low. TPLSM was applied to successfully follow more than 100 
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Several explanations may be proposed to explain the low brain metastasis efficiency. First, the 
brain metastasis cascade requires several steps, each of which is challenging for metastatic 
tumor cells, and the tough blood brain barrier (BBB) makes the brain vessel wall more 
difficult to overcome compared with other organs
152
. Another possible explanation is immune 
surveillance, as numerous immune cells, such as NK cells, DCs, monocytes, T cells, and B 
cells, are circulating and surveying in the blood, resulting in the elimination of many cells. 
Moreover, microglia and macrophages in the brain also exhibit immune response toward the 
metastatic tumor cells. Thus, both physical barriers and immune activation together lead to the 
inefficiency of brain metastasis formation. 
  





, we found that the absence of CX3CR1 significantly increased cerebral 
metastasis formation. This result seems to differ from the former literature. In liver cancer 
lacking CX3CR1, tumor metastasis is inhibited
62
, and in a glioma model, reduced CX3CR1 
expression delays tumor outgrowth
61
. We think the role of CX3CR1 may be different in 
different types of cancers, and in brain metastasis, it may facilitate TAMs recruitment and 
elimination of metastatic tumor cells, while in glioma and liver cancer, overexpression of 
CX3CR1 may help to establish a suppressive microenvironment that facilitates tumor 








As both microglia/macrophages express CX3CR1 receptor, the GFP signal could be 
investigated in both immune cells. Thus, in this thesis, we did not distinguish 
microglia/macrophages. However, TAMs have different origins and belong to different cell 
types. Thus, it is still necessary to investigate whether microglia/macrophages have different 
roles in cerebral metastasis formation. 
 
One strategy to distinguish microglia/macrophages could depend on turnover rate differences. 
In contrast to peripheral monocytes and inflammatory macrophages that exhibit rapid 
turnover
153








 mouse strain could 
successfully distinguish microglia/macrophages using two-photon in vivo microscopy. 




 mice, tamoxifen 
administration 30 days prior to the administration of DT successfully depleted approximately 
99% of microglia; however, monocytes in the blood or spleen did not show significant 
differences compared with the control mice. This finding indicated that microglia were 




Another selective microglial ablation strategy is the use of the CSF-1R inhibitor PLX3397. 
CSF-1R-dependent signaling is very important for the survival and activation of microglia. 
Extensive treatment with a brain-penetrant CSF-1R kinase inhibitor resulted in the 
elimination of ~99% of microglia throughout the brain. The depletion of microglia has no 
apparent gross deleterious effects in healthy mice: no signs of BBB damage, leukocyte 
recruitment, weight loss, or brain inflammation are
157
 observed after CSF-1R inhibition. Thus, 
the depletion of microglia using a small-molecule inhibitor introduces minimal disturbance to 
the brain and no alterations of peripheral leukocytes, enabling our group to selectively study 
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Another limitation of this thesis is the origin of the increasing TAMs. As we observed, a large 
number of TAMs infiltrated in the cerebral metastases, and thus, it was difficult to determine 
whether these cells were from the proliferation of TAMs or the peripheral blood.  
 
Furthermore, we did not distinguish the subtypes of TAMs in different steps of cerebral 
metastasis formation. The M1/M2 phenotypes of TAMs have different tumor cell roles, and 
their numbers and proportions will influence the fate of metastatic tumor cells. This part of 


















Although numerous studies have already focused on the role of TAMs in brain tumors, the 
detailed interactions between TAMs and metastasizing tumor cells in different steps of 
cerebral metastasis formation are still unclear. 
 
Here we established a syngeneic mouse model to follow the interactions between TAMs and 




 mice, we demonstrated that TAMs have close contacts with tumor 
cells in the early steps of cerebral metastasis formation. Close contact between TAMs and 
metastasizing tumor cells in the early steps of cerebral metastasis is beneficial, as TAMs have 




mice, we found that TAMs remained in a relatively stable state for 
intravascularly arrested tumor cells. We also observed a close contact between TAMs in the 
early steps of cerebral metastasis formation. 
 
After calculation of both the density and cell body volume of TAMs in both groups of mice, 
we found that both parameters were influenced by metastatic tumor cells. Both the density 
and cell body volume of TAMs gradually increased along with tumor proliferation. However, 
when metastasis regressed, both parameters decreased. A statistically significant difference in 
different steps of cerebral metastasis was observed compared with control group mice. 
 





 mice, we found effect of CX3CR1 on the infiltration of TAMs toward 
metastatic tumor cells, but not activation. As suggested by the quantitative data, fewer TAMs 
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were infiltrated in metastatic tumor lesions in CX3CR1-deficient mice, while the cell body 
volume of TAMs was similar without a significant difference. This finding indicated that 
CX3CR1 played an important role in the infiltration of TAMs toward metastatic tumor cells, 
but not their activation. 
 





 mice. After quantification, we observed the formation of significantly more 
tumor cells in micrometastases with reduced elimination in CX3CR1
GFP/GFP
 mice after 
extravasation. In the CX3CR1
GFP/GFP 
group, successful cerebral metastasis efficiency was 
much higher than in normal CX3CR1
GFP/wt
 mice. We further found that in both normal 
CX3CR1
GFP/wt
 and deficient CX3CR1
GFP/GFP 
mice, the efficiency of successful cerebral 
metastasis was very low at approximately 5% and 12%, respectively. 
 
Overall, we established a syngeneic cerebral metastasis model combining the chronic cranial 
window and two-photon microscopy. Using this model, we successfully investigated the 
interactions between TAMs and metastatic tumor cells in different steps of cerebral metastasis 
formation. We found that TAMs had close contact with metastatic tumor cells in the early 
steps of cerebral metastasis, and this close contact was beneficial for the eradication of 
metastatic tumor cells as the TAMs could exert engulfment functions toward metastatic tumor 
cells after extravasation. Moreover, in the CX3CR1-deficient group, we found that fewer 
TAMs were infiltrated in metastatic tumor lesions, potentially fewer tumor cells were 
eliminated during the first wave of immune surveillance and then more tumor cells formed 
micrometastases. Ultimately, the successful cerebral metastasis efficiency was higher in 
CX3CR1
GFP/GFP









In addition to focusing on the role of CX3CR1 in cerebral metastasis, another receptor we 
plan to investigate is CSF-1R. CSF-1R is very important for the proliferation, differentiation, 
and survival of TAMs
160
. Publications have shown that extensive treatment of mice using the 
CSF-1R inhibitor PLX3397 specifically depletes brain microglia, with a depletion efficiency 
reaching as high as 99%. Elimination of microglia in the adult CNS has no side effects such 
as body weight loss or deficits in behavior, cognition, or the blood brain barrier. Moreover, 
CSF-1R inhibition does not alter the spleen and blood immune cells; thus, the small molecule 
inhibitor PLX3397 can be used for the depletion of microglia and investigation of changes in 




We also investigated the depletion efficiency using our in vivo mouse model, and preliminary 
results showed a high depletion efficiency of PLX3397. After 1 month of treatment, 85-87% 
of the microglia/macrophages were depleted. 
Figure 31: High depletion efficiency of brain microglia/macrophages after CSF-1R inhibition using 
PLX3397.  
Control chow treatment did not alter the numbers of microglia/macrophages, while CSF-1R treatment led to a 




In the next steps, we plan to confirm the side effects of PLX3397 treatment. Immune cells 
from the blood, bone marrow, and spleen will be harvested and analyzed using FACS to 
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